1-chloro-4-(5-methylpyridin-2-yl)phthalazine | 1372642-37-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-chloro-4-(5-methylpyridin-2-yl)phthalazine
• CAS: 1372642-37-9
• 化学式: C₁₄H₁₀ClN₃
• 分子量: 255.707
• InChiKey: SHUMHEFQDPXEJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-(4-aminophenoxy)pyridin-3-yl)pyrimidin-2-amine 、 1-chloro-4-(5-methylpyridin-2-yl)phthalazine 以 仲丁醇 为溶剂， 反应 6.0h， 以43%的产率得到N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(5-methylpyridin-2-yl)phthalazin-1-amine
  参考文献：
  名称：

  Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines

  摘要：

  Efforts to improve upon the physical properties and metabolic stability of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compromised by increased polarity. Despite its high in vitro metabolic intrinsic clearance, 23r (AMG 900) showed acceptable pharmacokinetic properties and robust pharmacodynamic activity. Projecting from in vitro data to in vivo target coverage was not practical due to disjunctions between enzyme and cell data, complex and apparently contradictory indicators of binding kinetics, and unmeasurable free fraction in plasma. In contrast, it was straightforward to relate pharmacokinetics to pharmacodynamics and efficacy by following the time above a threshold concentration. On the basis of its oral route of administration, a selectivity profile that favors Aurora-driven pharmacology and its activity against multidrug-resistant cell lines, 23r was identified as a potential best-in-class Aurora kinase inhibitor. In phase 1 dose expansion studies with G-CSF support, 23r has shown promising single agent activity.

  DOI：

  10.1021/acs.jmedchem.5b00183
• 作为产物：
  描述：

  2-溴-5-甲基吡啶 在 肼 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 1-chloro-4-(5-methylpyridin-2-yl)phthalazine
  参考文献：
  名称：

  Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines

  摘要：

  Efforts to improve upon the physical properties and metabolic stability of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compromised by increased polarity. Despite its high in vitro metabolic intrinsic clearance, 23r (AMG 900) showed acceptable pharmacokinetic properties and robust pharmacodynamic activity. Projecting from in vitro data to in vivo target coverage was not practical due to disjunctions between enzyme and cell data, complex and apparently contradictory indicators of binding kinetics, and unmeasurable free fraction in plasma. In contrast, it was straightforward to relate pharmacokinetics to pharmacodynamics and efficacy by following the time above a threshold concentration. On the basis of its oral route of administration, a selectivity profile that favors Aurora-driven pharmacology and its activity against multidrug-resistant cell lines, 23r was identified as a potential best-in-class Aurora kinase inhibitor. In phase 1 dose expansion studies with G-CSF support, 23r has shown promising single agent activity.

  DOI：

  10.1021/acs.jmedchem.5b00183

文献信息

• Synthesis of 4-Substituted Chlorophthalazines, Dihydrobenzoazepinediones, 2-Pyrazolylbenzoic Acid, and 2-Pyrazolylbenzohydrazide via 3-Substituted 3-Hydroxyisoindolin-1-ones
  作者：Hanh Nho Nguyen、Victor J. Cee、Holly L. Deak、Bingfan Du、Kathleen Panter Faber、Hakan Gunaydin、Brian L. Hodous、Steven L. Hollis、Paul H. Krolikowski、Philip R. Olivieri、Vinod F. Patel、Karina Romero、Laurie B. Schenkel、Stephanie D. Geuns-Meyer

  DOI：10.1021/jo3000628

  日期：2012.4.20

  hydrazine, followed by chlorination with POCl3. We have also discovered two novel transformations of 3-vinyl- and 3-alkynyl-3-hydroxyisoindolinones. Addition of vinyl organometallic reagents to N,N-dimethylaminophthalimide (8a) provided dihydrobenzoazepinediones 15a–15c via the proposed ring expansion of 3-vinyl-3-hydroxyisoindolinone intermediates. 3-Alkynyl-3-hydroxyisoindolinones react with hydrazine and

  在本文中，我们描述了以良好的总收率进行的4-取代的氯邻苯二甲腈的一般三步合成。在关键步骤中，N，N-二甲基氨基邻苯二甲酰亚胺（8a）指导烷基，芳基和杂芳基有机金属试剂的选择性单加成反应，得到3-取代的3-羟基异吲哚满酮9b，9i - 9am。通过与肼反应，然后用POCl 3氯化，许多羟基异吲哚啉酮可转化为氯酞嗪1b - 1v。我们还发现了3-乙烯基和3-炔基-3-羟基异吲哚满酮的两个新颖的转化。将乙烯基有机金属试剂添加到N，N-二甲基氨基邻苯二甲酰亚胺（8a）通过提议的3-乙烯基-3-羟基异吲哚满酮中间体的扩环作用提供了二氢苯并氮杂氮杂二酮15a - 15c。3-炔基-3-羟基异吲哚啉酮与肼和取代的肼反应，生成2-吡唑基苯甲酸16a - 16d和2-吡唑基苯并酰肼17a - 17g，而不是预期的炔基酞菁。
• Discovery of <i>N</i>-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines
  作者：Stephanie Geuns-Meyer、Victor J. Cee、Holly L. Deak、Bingfan Du、Brian L. Hodous、Hanh Nho Nguyen、Philip R. Olivieri、Laurie B. Schenkel、Karina R. Vaida、Paul Andrews、Annette Bak、Xuhai Be、Pedro J. Beltran、Tammy L. Bush、Mary K. Chaves、Grace Chung、Yang Dai、Patrick Eden、Kelly Hanestad、Liyue Huang、Min-Hwa Jasmine Lin、Jin Tang、Beth Ziegler、Robert Radinsky、Richard Kendall、Vinod F. Patel、Marc Payton

  DOI：10.1021/acs.jmedchem.5b00183

  日期：2015.7.9

  Efforts to improve upon the physical properties and metabolic stability of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compromised by increased polarity. Despite its high in vitro metabolic intrinsic clearance, 23r (AMG 900) showed acceptable pharmacokinetic properties and robust pharmacodynamic activity. Projecting from in vitro data to in vivo target coverage was not practical due to disjunctions between enzyme and cell data, complex and apparently contradictory indicators of binding kinetics, and unmeasurable free fraction in plasma. In contrast, it was straightforward to relate pharmacokinetics to pharmacodynamics and efficacy by following the time above a threshold concentration. On the basis of its oral route of administration, a selectivity profile that favors Aurora-driven pharmacology and its activity against multidrug-resistant cell lines, 23r was identified as a potential best-in-class Aurora kinase inhibitor. In phase 1 dose expansion studies with G-CSF support, 23r has shown promising single agent activity.